<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30983" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Varicella-Zoster Immune Globulin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sidhu</surname>
            <given-names>Abhitej S.</given-names>
          </name>
          <aff>Bharati Vidyapeeth Medical College, Pune, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akhondi</surname>
            <given-names>Hossein</given-names>
          </name>
          <aff>University of Nevada</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abhitej Sidhu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hossein Akhondi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30983.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Varicella-zoster immune globulin (VZIG) plays a crucial role in averting varicella infection in high-risk individuals as a post-exposure prevention and treatment option. Classified within the "Opportunistic Infections and Co-infections" treatment category, VZIG has proven effective in mitigating the severity of varicella in susceptible patients. This educational activity explores key aspects of VZIG therapy, encompassing indications, contraindications, mechanisms of action, and potential adverse effects. This program also underscores the vital role of interprofessional teams in managing possible infections among high-risk individuals, providing a shield against varicella and its associated complications.</p>
        <p>Participants in this session will acquire a comprehensive understanding of the essential elements of VZIG therapy, enabling them to make informed decisions and implement appropriate measures for post-exposure prophylaxis. Highlighting the clinical significance of VZIG, this activity aims to empower healthcare providers with the requisite knowledge to identify high-risk individuals, recommend proper administration, and effectively mitigate varicella-related risks. By addressing the complexities of VZIG therapy, this activity advocates for an interprofessional approach, ensuring comprehensive care and prophylactic measures against varicella within vulnerable populations.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at high risk of severe varicella infection necessitating varicella-zoster immune globulin (VZIG) prophylaxis based on age, immunocompromised status, or lack of evidence of immunity.</p></list-item><list-item><p>Implement appropriate dosing, timing, and administering VZIG post-exposure prevention in high-risk individuals to prevent severe varicella complications.</p></list-item><list-item><p>Assess the efficacy of VZIG therapy by monitoring clinical response, adverse effects, and serological indicators post-administration.</p></list-item><list-item><p>Implement effective communication with patients and caregivers about the purpose, benefits, and potential risks associated with varicella immune globulin administration.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30983&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30983">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30983.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Varicella-zoster virus (HHV-3) is a highly contagious virus that can cause either chickenpox or herpes zoster.&#x000a0;The virus is transmitted mainly through inhalation of the virus-infected aerosolized droplets. HHV-3 initially presents as an upper airway infection, which enters the circulation 2&#x000a0;to 3 days before causing another bout of viremia (after 10&#x000a0;to 12 days) when it presents with a characteristic pruritic, vesicular rash over the skin and mucous membranes. Additional features include fever and a loss of appetite. This rash typically begins on the face and the trunk and then spreads to the extremities, usually resolving in 4&#x000a0;to 7 days. Individuals produce IgA, IgM, and IgG as a response to the infection, and IgG antibodies provide lifelong immunity against the virus. Varicella-zoster virus (VZV) can remain dormant in the sensory nerves after a primary varicella infection. Its reactivation can cause herpes zoster, a painful vesicular rash along a dermatome that does not cross the midline.<xref ref-type="bibr" rid="article-30983.r1">[1]</xref></p>
        <p>The FDA has approved VZV vaccinations, a decision that has significantly decreased the number of patients admitted with varicella annually in the United States. The vaccines are available for patients 12 months and older, making chickenpox a preventable disease. However, immunocompromised and pregnant patients are ineligible for these vaccinations.<xref ref-type="bibr" rid="article-30983.r2">[2]</xref>&#x000a0;</p>
        <p>Varicella-zoster immune globulin (VZIG) was first researched in the 1960s and prepared from samples from patients recovering from varicella-zoster.&#x000a0;The drug reduces the severity and attack rates of primary varicella. Following modification in the late 1970s, the varicella immune globulin came onto the market for high-risk individuals with varicella exposure, and it underwent further revision to the current immune globulin sold in the United States.</p>
        <p>
<bold>FDA-Approved Indication</bold>
</p>
        <p>Varicella-zoster immune globulin should be considered for post-exposure prevention in individuals with a high risk of developing severe disease, lacking immunity, or ineligible for vaccination.<xref ref-type="bibr" rid="article-30983.r3">[3]</xref>&#x000a0;The CDC recommends varicella-zoster immune globulin either immediately or up to 10 days following exposure for maximal efficacy for the following patient groups:</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunocompromised patients with no evidence of immunity (including those who have primary or secondary immunodeficiencies), patients with an underlying neoplastic disease, and persons receiving immunosuppressive therapies are also indicated for patients undergoing hematopoietic cell transplantation who have not yet been re-immunized against varicella infection.</p>
          </list-item>
          <list-item>
            <p>Mothers of newborn infants who have signs and symptoms of varicella around the time of delivery (ie,&#x000a0;5 days before delivery and up to&#x000a0;2 days after); VZV transmission can be transplacental (in utero) or can happen during a contact perinatally or postnatally.</p>
          </list-item>
          <list-item>
            <p>Premature infants hospitalized or born at &#x02265;28 weeks of gestation whose mothers lack evidence of immunity to varicella.</p>
          </list-item>
          <list-item>
            <p>Premature infants hospitalized or born at &#x0003c;28 weeks of gestation or weighing &#x0003c;1000g at birth, even if their mothers have evidence of immunity to varicella.</p>
          </list-item>
          <list-item>
            <p>Pregnant women who lack evidence of immunity.</p>
          </list-item>
        </list>
        <p>Immunocompromised patients who were receiving a monthly high dose of intravenous immune globulin (IVIG) and received the dose &#x0003c;3 weeks before exposure were likely to be protected from varicella.<xref ref-type="bibr" rid="article-30983.r3">[3]</xref><xref ref-type="bibr" rid="article-30983.r4">[4]</xref><xref ref-type="bibr" rid="article-30983.r5">[5]</xref></p>
      </sec>
      <sec id="article-30983.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>B lymphocytes (plasma cells) produce immunoglobulins, which function as antibodies and can recognize a vast spectrum of antigenic epitopes. Adequate functioning of these immunoglobulins is essential for a healthy humoral immune response. Each immunoglobulin structure is unique, and an extensive collection of immunoglobulins allows the body to respond to various antigens, a process termed&#x000a0;passive protection. This passive protection protects the patient until&#x000a0;they can produce&#x000a0;antibodies against VZV.<xref ref-type="bibr" rid="article-30983.r6">[6]</xref></p>
        <p>Human immunoglobulin products are produced from an amalgamation of plasma from several donors; this ensures that the final product contains a wide variety of antibody repertoires with a collection of variable domains of antibodies within the regular serum. The IgG molecules must have suitable functional activities such as complement-mediated bactericidal activity, virus-neutralizing activity, opsonization (ie, marking a pathogen for destruction), and the ability to inactivate toxins to create an effective immune response against various microorganisms.</p>
        <p>The herpes zoster immune globulin contains antibodies (IgG) from pooled human plasma of individuals with high varicella-zoster titers, providing passive immunity.<xref ref-type="bibr" rid="article-30983.r7">[7]</xref><xref ref-type="bibr" rid="article-30983.r8">[8]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;IV varicella-zoster immune globulin administration generally persists for 6 weeks or longer. Following&#x000a0;IM administration of varicella immune globulin products, varicella antibodies are detectable within 2&#x000a0;or 3 days. VZIG levels are expected to&#x000a0;peak within 3&#x000a0;to 7 days of administration.</p>
        <p><bold>Distribution:</bold>&#x000a0;Intramuscular varicella-zoster immune globulin administration achieves nearly 100% bioavailability.&#x000a0;</p>
        <p><bold>Metabolism:</bold> Metabolism of immune globulins occurs in the reticuloendothelial system.</p>
        <p><bold>Elimination:</bold> Excretion information is unavailable, but the drug exhibits a half-life of 24 to 30 days following IM administration.</p>
      </sec>
      <sec id="article-30983.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms</bold>
</p>
        <p>Human immunoglobulin products&#x000a0;are available as intravenous immune globulin (IVIG), subcutaneous immune globulin (SCIG), and intramuscular immune globulin (IMIG). In the United States, varicella-zoster immune globulin is available only as intramuscular immune globulin (IMIG). The FDA approved&#x000a0;the drug in December 2012.</p>
        <p>Varicella-zoster immune globulin comes in 125 IU per 1.2 mL vials, and administration should only be intramuscular and as directed by the manufacturer. No dose adjustments are recommended for renal or hepatic impairment. Individuals who later become eligible for vaccination should receive varicella vaccine &#x02265;5 months after varicella-zoster immune globulin administration.<xref ref-type="bibr" rid="article-30983.r3">[3]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Post-exposure varicella-zoster prevention should start as soon as possible following exposure.&#x000a0;The drug may be given up to 10 days post-exposure. The dosing for all patients is based on weight:</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0003c;30 kg: 375 units IM for a single dose&#x000a0;</p>
          </list-item>
          <list-item>
            <p>30.1 to 40 kg: 500 units IM for a single dose</p>
          </list-item>
          <list-item>
            <p>&#x0003e;40 kg: 625 units IM for a single dose</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0003c;2 kg: 62.5 units IM for a single dose.</p>
          </list-item>
          <list-item>
            <p>2.1 to 10 kg:&#x000a0;125 units IM for a single dose.</p>
          </list-item>
          <list-item>
            <p>10.1 to 20 kg: 250 units IM for a single dose.</p>
          </list-item>
          <list-item>
            <p>20.1 to 30 kg:&#x000a0;375 units IM for a single dose.</p>
          </list-item>
          <list-item>
            <p>30.1 to 40 kg: 500 units IM for a single dose.</p>
          </list-item>
          <list-item>
            <p>&#x0003e;40 kg: 625 units IM for a single dose.</p>
          </list-item>
        </list>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Renal impairment dosing:</bold> No dose adjustment is necessary; dosing for dialysis patients is undefined.</p>
        <p><bold>Hepatic impairment dosing:</bold> Hepatic dosing is undefined.</p>
        <p><bold>Pregnancy considerations:</bold> There is no known risk of fetal harm based on human data.</p>
        <p><bold>Breastfeeding considerations:</bold> No human data is available to assess the risk of infant harm or effects on milk production; clinicians should weigh risks vs benefits.</p>
        <p><bold>Pediatric patients:</bold> See pediatric dosing above.</p>
        <p><bold>Older patients:</bold> No limitations on dosing based on age for older patients.</p>
      </sec>
      <sec id="article-30983.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Local pain at the injection site is the most typical adverse reaction from&#x000a0;VZIG administration. One percent to 10% of patients have developed headaches, fatigue, and chills. Other less common reactions include skin rash and nausea. Very rarely, patients also develop DVT, serum sickness, hypersensitivity reaction, and thrombosis.<xref ref-type="bibr" rid="article-30983.r9">[9]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Varicella immune globulin should not be used with vaccine immune globulin, as the combination may increase the risk of thromboembolism. This risk is also present with numerous other agents at a lower level that may require modifying treatment. As always, a thorough medication reconciliation is necessary.</p>
      </sec>
      <sec id="article-30983.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Varicella-zoster immune globulin administration is contraindicated in patients with a history of IgA deficiency. Contraindications also include patients with a history of anaphylaxis to human immune globulin. IV use is also contraindicated. Clinicians should&#x000a0;be aware that administration of the drug once the clinical illness has developed is ineffective.<xref ref-type="bibr" rid="article-30983.r10">[10]</xref><xref ref-type="bibr" rid="article-30983.r4">[4]</xref></p>
      </sec>
      <sec id="article-30983.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>For patients receiving varicella-zoster immune globulin, observation for 28 days after exposure for any signs and symptoms of varicella infection is recommended. The administration of immune globulin might increase the disease's incubation period by&#x000a0;&#x02265;1 week. Antiviral therapy should start immediately if a patient develops signs and symptoms of varicella.<xref ref-type="bibr" rid="article-30983.r3">[3]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-30983.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Since the drug is prepared from a human plasma pool, it may contain other infectious agents.&#x000a0;The LD<sub>50</sub> is undetermined, as the maximal dose did not kill any experimental animals.</p>
      </sec>
      <sec id="article-30983.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While the demand for varicella-zoster immune globulin has reduced significantly, it is essential to remember that exposure to varicella and herpes zoster&#x000a0;can still occur. Early recognition of exposure is critical in pregnant females as there is a high risk of maternal complications due to varicella infection. Using varicella-zoster immune globulin helps modify disease and reduces maternal morbidity.</p>
        <p>Similar principles also apply to immunocompromised patients and premature neonates.<xref ref-type="bibr" rid="article-30983.r4">[4]</xref>&#x000a0;Varicella-zoster immune globulin must not be confused with the varicella virus vaccine, which&#x000a0;is contraindicated during pregnancy and can be given erroneously to pregnant women exposed to the varicella virus. Additionally, clinicians must remember to administer varicella-zoster immune globulin immediately after exposure and within 10 days.<xref ref-type="bibr" rid="article-30983.r11">[11]</xref><xref ref-type="bibr" rid="article-30983.r12">[12]</xref><xref ref-type="bibr" rid="article-30983.r5">[5]</xref><xref ref-type="bibr" rid="article-30983.r3">[3]</xref></p>
        <p>An interprofessional team&#x000a0;approach is optimal for administering therapy with&#x000a0;varicella-zoster immune globulin. This interprofessional team will include&#x000a0;physicians, advanced practice practitioners, nursing staff, and pharmacists.</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Varicella-zoster immune globulin has minimal adverse reactions and toxicity. Studies have shown that early administration, especially in pregnant women, decreases maternal morbidity and that exposed patients have good clinical outcomes. Additionally, varicella-zoster immune globulin prophylaxis reduced the incidence and morbidity&#x000a0;of varicella-zoster in preterm newborns and infants exposed in utero.<xref ref-type="bibr" rid="article-30983.r13">[13]</xref></p>
      </sec>
      <sec id="article-30983.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30983&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30983">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30983/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30983">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30983.s11">
        <title>References</title>
        <ref id="article-30983.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ayoade</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Varicella-Zoster Virus (Chickenpox)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>10</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">28846365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kota</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grella</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <chapter-title>Varicella (Chickenpox) Vaccine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">28722975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>Updated recommendations for use of VariZIG--United States, 2013.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2013</year>
            <month>Jul</month>
            <day>19</day>
            <volume>62</volume>
            <issue>28</issue>
            <fpage>574</fpage>
            <page-range>574-6</page-range>
            <pub-id pub-id-type="pmid">23863705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2012</year>
            <month>Mar</month>
            <day>30</day>
            <volume>61</volume>
            <issue>12</issue>
            <fpage>212</fpage>
            <pub-id pub-id-type="pmid">22456121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2006</year>
            <month>Mar</month>
            <day>03</day>
            <volume>55</volume>
            <issue>8</issue>
            <fpage>209</fpage>
            <page-range>209-10</page-range>
            <pub-id pub-id-type="pmid">16511443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lachiewicz</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Varicella-zoster virus post-exposure management and prophylaxis: A review.</article-title>
            <source>Prev Med Rep</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>16</volume>
            <fpage>101016</fpage>
            <pub-id pub-id-type="pmid">31890472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lam</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Whitsett</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>McNicholl</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Immunologically active proteins in intravenous immunoglobulin.</article-title>
            <source>Lancet</source>
            <year>1993</year>
            <month>Sep</month>
            <day>11</day>
            <volume>342</volume>
            <issue>8872</issue>
            <fpage>678</fpage>
            <pub-id pub-id-type="pmid">8103161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Da&#x000eb;ron</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fc receptor biology.</article-title>
            <source>Annu Rev Immunol</source>
            <year>1997</year>
            <volume>15</volume>
            <fpage>203</fpage>
            <page-range>203-34</page-range>
            <pub-id pub-id-type="pmid">9143687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jhaveri</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Myths and Misconceptions: Varicella-Zoster Virus Exposure, Infection Risks, Complications, and Treatments.</article-title>
            <source>Clin Ther</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>9</issue>
            <fpage>1816</fpage>
            <page-range>1816-1822</page-range>
            <pub-id pub-id-type="pmid">31326126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamont</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Carrington</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mazaki-Tovi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kusanovic</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Vaisbuch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Varicella-zoster virus (chickenpox) infection in pregnancy.</article-title>
            <source>BJOG</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>118</volume>
            <issue>10</issue>
            <fpage>1155</fpage>
            <page-range>1155-62</page-range>
            <pub-id pub-id-type="pmid">21585641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000fc;ris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chaves</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seward</surname>
                <given-names>JF</given-names>
              </name>
              <collab>Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2007</year>
            <month>Jun</month>
            <day>22</day>
            <volume>56</volume>
            <issue>RR-4</issue>
            <fpage>1</fpage>
            <page-range>1-40</page-range>
            <pub-id pub-id-type="pmid">17585291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Duchon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Swamy</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Gershon</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>e0217749</fpage>
            <pub-id pub-id-type="pmid">31269033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30983.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duchon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gershon</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Safety and Varicella Outcomes in In Utero-Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2020</year>
            <month>Sep</month>
            <day>17</day>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>449</fpage>
            <page-range>449-453</page-range>
            <pub-id pub-id-type="pmid">31774916</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
